WASHINGTON, D.C. - The Federal Trade Commission told the U.S. Supreme Court in oral arguments on March 25 that the court should treat reverse-payment settlements of patent litigation between the holder of a drug patent and potential generic manufacturers of the drug as presumptively invalid (Federal Trade Commission v. Actavis, Inc., et al., No. 12-416, U.S. Sup.)....(read more)![]()
↧